Publication Date




Download Full Text (717 KB)


Background: Intravenous immune globulin (IVIG) is a plasma-derived product from pooled donors. It has six FDA approved indications. It is also considered standard of care for a few other conditions in specific populations. Additionally, there is growing non-evidence-based use. Due to a global shortage, IVIG has become increasing difficult to obtain.

. . . .

Conclusions: Development, implementation, and promotion of adherence to an evidence-based criterion allowed our scarce IVIG supply to be sustained. Further refinement of the criteria for use is ongoing, as is an evaluation of IVIG utilization by indication, pre- and post-implementation. This process can be applied to other situations of scarce resources

MeSH Keywords

Immunoglobulins, Intravenous; Evidence-Based Practice; Resource Allocation; Quality Improvement




Health and Medical Administration | Pharmacy and Pharmaceutical Sciences


National Healthcare Quality Week

Development and Implementation of an Evidence-Based Process for Scarce Resource Allocation



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.